Safety Profile
Known Safety Concerns
- Hypermagnesaemia in renal impairment — potentially life-threatening
- Diarrhoea, nausea and abdominal cramping at high doses
- May reduce absorption of certain antibiotics (tetracyclines, fluoroquinolones)
- UL: 350 mg/day elemental magnesium from supplements (excluding food)
Contraindications
- Hypermagnesaemia in renal impairment — potentially life-threatening
- Diarrhoea, nausea and abdominal cramping at high doses
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Magnesium glycinate is a chelated form with high bioavailability and low GI side effects. Magnesium is essential for over 300 enzymatic reactions. At standard doses it is very well tolerated. Excess magnesium is excreted renally in healthy individuals. Toxicity is a concern in renal impairment where excretion is reduced. The UL for supplemental magnesium is 350 mg/day (elemental).
Biological and Chemical Classification
- Scientific Name
- Magnesium bisglycinate / Magnesium diglycinate
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 7 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- Hypermagnesaemia in renal impairment — potentially life-threatening
- Diarrhoea, nausea and abdominal cramping at high doses
- May reduce absorption of certain antibiotics (tetracyclines, fluoroquinolones)
- UL: 350 mg/day elemental magnesium from supplements (excluding food)
The available scientific evidence for Magnesium (Glycinate) indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 7/40 |
| Evidence consistency | 20/20 |
| Safety signals | 6/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 7 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 7 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 23 მარ 2026, 15:06
Evidence Distribution
-
Observational / other LOW evidence YELLOWMagnesium - The Silent Partner or the Next Vitamin D? Shifting Paradigm in Mineral Metabolism in Health and Disease. ↗Ahmed S et al.. Magnesium - The Silent Partner or the Next Vitamin D? Shifting Paradigm in Mineral Metabolism in Health and Disease.. EJIFCC. 2026. PMID:41659294.PMID 41659294 ↗Journal EJIFCCYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41659294/
-
Observational / other LOW evidence YELLOWA Challenging Case of Hypercalcemia Caused by a Novel Homozygous Variant Missense Mutation in the CYP24A1 Gene. ↗Ahsan T et al.. A Challenging Case of Hypercalcemia Caused by a Novel Homozygous Variant Missense Mutation in the CYP24A1 Gene.. JCEM Case Rep. 2026. PMID:41356536.PMID 41356536 ↗Journal JCEM Case RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41356536/
-
Observational / other LOW evidence YELLOWEffect of chronic administration of magnesium supplement (magnesium glycinate) on male albino wistar rats' intestinal (Ileum) motility, body weight changes, food and… ↗Aniebo Umoh E et al.. Effect of chronic administration of magnesium supplement (magnesium glycinate) on male albino wistar rats' intestinal (Ileum) motility, body weight changes, food and water intake.. Heliyon. 2023. PMID:37636381.PMID 37636381 ↗Journal HeliyonYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/37636381/
-
Observational / other LOW evidence YELLOWCombined vitamin D and magnesium supplementation does not influence markers of bone turnover or glycemic control: A randomized controlled clinical trial. ↗Dall RD et al.. Combined vitamin D and magnesium supplementation does not influence markers of bone turnover or glycemic control: A randomized controlled clinical trial.. Nutr Res. 2023. PMID:36640582.PMID 36640582 ↗Journal Nutr ResYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/36640582/
-
Observational / other LOW evidence YELLOWMagnesium yields opposite effects on the nuclear and cytosolic cascades of apoptosis in different rat brain regions. ↗Kizildau011f S et al.. Magnesium yields opposite effects on the nuclear and cytosolic cascades of apoptosis in different rat brain regions.. Eur Rev Med Pharmacol Sci. 2022. PMID:36196701.PMID 36196701 ↗Journal Eur Rev Med Pharmacol SciYear 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/36196701/
-
Observational / other LOW evidence YELLOWThe effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled… ↗Cheung MM et al.. The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial.. Nutrition. 2022. PMID:35576873.PMID 35576873 ↗Journal NutritionYear 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/35576873/
-
Observational / other LOW evidence YELLOWDose-Dependent Absorption Profile of Different Magnesium Compounds. ↗Ates M et al.. Dose-Dependent Absorption Profile of Different Magnesium Compounds.. Biol Trace Elem Res. 2019. PMID:30761462.PMID 30761462 ↗Journal Biol Trace Elem ResYear 2019Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/30761462/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Magnesium (Glycinate). Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Magnesium (Glycinate)
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.